idarubicin has been researched along with Emesis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, S; Avvisati, G; Baccarani, M; Cantore, N; Di Bona, E; Ferrara, F; Fioritoni, G; Gallo, E; Invernizzi, R; Lazzarino, M; Liso, V; Lo-Coco, F; Mandelli, F; Mariani, G; Petti, MC; Ricciuti, F; Selleri, C; Sica, S; Vegna, ML; Veneri, D | 1 |
| Cotter, SM; L'Heureux, DA; Moore, AS; Rand, WM; Ruslander, D | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Yamada, K | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Bozzi, D; Brandi, M; Calabrese, P; De Lena, M; Romito, S | 1 |
| Martoni, A; Pacciarini, MA; Pannuti, F | 1 |
4 trial(s) available for idarubicin and Emesis
| Article | Year |
|---|---|
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hemorrhage; Humans; Idarubicin; Infections; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Vomiting | 2002 |
[Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vomiting | 1993 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Vomiting | 1985 |
2 other study(ies) available for idarubicin and Emesis
| Article | Year |
|---|---|
Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
Topics: Administration, Oral; Animals; Anorexia; Cat Diseases; Cats; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Idarubicin; Leukopenia; Lymphoma; Male; Neoplasms; Vomiting | 1995 |
4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Daunorubicin; Female; Humans; Idarubicin; Middle Aged; Nausea; Soft Tissue Neoplasms; Stomach Ulcer; Vomiting | 1988 |